A5043116308- Bone health and treatments
- Bone health and osteoporosis research
- Cancer Immunotherapy and Biomarkers
- Bone and Joint Diseases
- Lung Cancer Treatments and Mutations
- Health Systems, Economic Evaluations, Quality of Life
- Medication Adherence and Compliance
- Pharmaceutical Practices and Patient Outcomes
- Biosimilars and Bioanalytical Methods
- Pharmaceutical studies and practices
- Hip and Femur Fractures
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Bone fractures and treatments
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Atrial Fibrillation Management and Outcomes
- Economic and Financial Impacts of Cancer
- Antiplatelet Therapy and Cardiovascular Diseases
- Schizophrenia research and treatment
- Cardiac Arrhythmias and Treatments
- Lung Cancer Research Studies
- Cardiac Imaging and Diagnostics
- Pharmaceutical Economics and Policy
Kaiser Permanente
2016-2025
Westmead Hospital
2004-2022
The University of Sydney
2011-2022
King's College London
2021
Guy's Hospital
2021
Kaiser Permanente Oakland Medical Center
2021
Midwestern University
2020
American Medical Research
2019-2020
Blueprint Medicines (United States)
2020
Analysis Group (United States)
2020
Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line treatment patients with mTNBC.
Little information exists about the consequences of limits on prescription-drug benefits for Medicare beneficiaries.
Background: The Food and Drug Administration has issued a public health advisory regarding cancer risk from topical calcineurin inhibitors. Objective: To compare the rates of among patients with common dermatologic conditions who were exposed or not to Methods: A retrospective cohort observational study used data an integrated healthcare delivery system on 953,064 subjects diagnoses atopic dermatitis eczema between 2001 December 2004. main endpoint was initial diagnosis. Chart review...
Objectives Concomitant use of cytochrome P-450 and P-glycoprotein (CYP 3A4/P-gp) inducing antiseizure medications direct oral anticoagulants (DOAC) may result in reduced DOAC effectiveness, but study results are inconsistent variable quality. The purpose this was to assess the safety concomitant CYP 3A4/P-gp use. Methods This a retrospective cohort adult patients who were newly, concomitantly receiving (apixaban, dabigatran, or rivaroxaban) either inducer (carbamazepine, phenytoin,...
There may be patient concerns with switching to a biosimilar product. The purpose of this study was describe the perspectives patients inflammatory bowel diseases (IBD) after from reference product (RP) adalimumab adalimumab-atto. This telephonic survey US IBD conducted in June-July 2023 among adult, English-speaking who were switched adalimumab-atto RP within previous 100 days, and receiving at time survey. Consented participants queried on safety effectiveness, cost, preference, education...
Study Objective To evaluate clinical and safety outcomes among transplant recipients whose tacrolimus was converted from the brand‐name formulation to a generic formulation. Design Retrospective analysis. Data Source Clinical databases electronic records large, integrated health care system in California. Patients A total of 234 clinically stable, adult (renal, liver, heart) between O ctober 1, 2010, D ecember 31, according physician‐approved protocol. Measurements Main Results For each...
BACKGROUND: In the elderly, use of medications may increase propensity for adverse drug events due to alterations in pharmacokinetic and pharmacodynamic profiles from normal aging processes. Deprescribing is planned supervised process dose reduction or discontinuation that lead harm are no longer beneficial. While there studies detailing strategies deprescribe such as benzodiazepines antipsychotics nursing homes patients with dementia, a lack guidance safely chronic medications,...
The viability and stability of the Medicare Part D prescription drug program depend on accurate risk-adjusted payments. current approach, hierarchical condition categories (RxHCCs), uses diagnosis demographic information to predict future costs. We evaluated performance multiple approaches for predicting 2006 costs plan liability. RxHCCs explain 12 percent variation in actual costs, overpredict beneficiaries with low underpredict high Combining individual-level prior-year use greatly...